Mount Yale Investment Advisors LLC increased its position in shares of Icon Plc (NASDAQ:ICLR) by 4.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,845 shares of the medical research company’s stock after acquiring an additional 574 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Icon were worth $1,967,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of ICLR. Eaton Vance Management bought a new position in shares of Icon in the 1st quarter worth $949,000. Schwab Charles Investment Management Inc. increased its holdings in shares of Icon by 10.1% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 23,861 shares of the medical research company’s stock worth $2,819,000 after buying an additional 2,184 shares during the last quarter. Private Advisor Group LLC increased its holdings in shares of Icon by 59.4% in the 1st quarter. Private Advisor Group LLC now owns 2,932 shares of the medical research company’s stock worth $346,000 after buying an additional 1,093 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Icon by 6.4% in the 1st quarter. Northern Trust Corp now owns 292,907 shares of the medical research company’s stock worth $34,604,000 after buying an additional 17,650 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in shares of Icon by 15.7% in the 1st quarter. BlackRock Inc. now owns 45,357 shares of the medical research company’s stock worth $5,358,000 after buying an additional 6,156 shares during the last quarter. 87.92% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have recently issued reports on ICLR shares. Robert W. Baird upped their price objective on shares of Icon from $154.00 to $157.00 and gave the company an “outperform” rating in a research note on Tuesday, September 11th. Jefferies Financial Group upped their price objective on shares of Icon to $150.00 and gave the company a “buy” rating in a research note on Friday, June 1st. Mizuho set a $146.00 price objective on shares of Icon and gave the company a “hold” rating in a research note on Monday, August 6th. BidaskClub raised shares of Icon from a “hold” rating to a “buy” rating in a research note on Wednesday, May 23rd. Finally, Credit Suisse Group upped their price objective on shares of Icon from $131.00 to $144.00 and gave the company an “outperform” rating in a research note on Tuesday, June 19th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $146.22.

Shares of ICLR opened at $146.65 on Wednesday. The firm has a market cap of $7.99 billion, a price-to-earnings ratio of 27.21, a PEG ratio of 2.12 and a beta of 0.35. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.10 and a quick ratio of 2.10. Icon Plc has a twelve month low of $101.22 and a twelve month high of $150.18.

Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, July 25th. The medical research company reported $1.31 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.48 by ($0.17). The firm had revenue of $641.60 million for the quarter, compared to analysts’ expectations of $618.64 million. Icon had a net margin of 13.69% and a return on equity of 26.35%. The company’s quarterly revenue was up 48.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.34 EPS. equities research analysts forecast that Icon Plc will post 6.08 EPS for the current fiscal year.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Recommended Story: Determine Your Level of Risk Tolerance

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.